Tibofem
Designed to support estrogen receptor activation to manage menopausal hot flashes and alleviate bone loss.
- Categories
- Women's Health · Menopause & HRT · Hormone Therapy
- Active ingredient
- Tibolone
- Route
- Oral use
- Form
- Tablet
- Strengths
- 2.5mg
Prescription and consultation requirements for Tibofem vary by destination and are determined by the fulfilment partner.
Tibofem details
- Alternative names
- tibolone
- Therapeutic class
- Synthetic Steroid
- Pharmacological class
- Estrogen Receptor Agonist
- Contraindications
- pregnancy; history of breast cancer; active thromboembolic disease
- Minor side effects
- vaginal discharge; headache; abdominal pain
- Moderate side effects
- breast pain; weight change; hirsutism
- Dosage forms
- Tablet
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Manufacturer
- Cipla Ltd
- Onset Time
- 2–4 weeks
- Duration
- 24 hours
- Storage instructions
- Store below 25°C.
- Drug interactions
- Warfarin; Anticonvulsants
- Age restrictions
- Approved for postmenopausal adult females.
Serious side effects
stroke, requires immediate medical attention; endometrial cancer, requires immediate medical attention
Patient summary
designed to support estrogen receptor activation to manage menopausal hot flashes and alleviate bone loss.
Mechanism of action
Metabolises into compounds that exert tissue-specific estrogenic, progestogenic, and androgenic activity, normalising endocrine function.
Pregnancy and breastfeeding
TGA Category X: Highly contraindicated. Strictly avoid in pregnancy. Breastfeeding: Contraindicated.